To Our New Jersey Life Sciences Community:
Welcome to another edition of The Weekender.
Eli Lilly Receives Fourth FDA Approval For CYRAMZA
Eli Lilly and Company received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA (ramucirumab), now also indicated in combination with FOLFIRI (irinotecan, folinic acid and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
Assembly Committee Releases Bill A2477
Proposed legislation that will allow greater patient access to more affordable FDA-approved biologic medicines was passed unanimously by the New Jersey Assembly Health and Human Services Committee on May 7. BioNJ would like to thank Assemblywoman Pamela Lampitt, Assemblyman Herb Conaway, Jr., M.D., Assemblyman Daniel Benson, Assemblyman Angel Fuentes, Assemblywoman Shavonda Sumter, Assemblywoman Nancy Muñoz and Assemblywoman Nancy Pinkin for sponsoring the bill and for their continued support in finding cures for Patients.
2015 Technology Business Tax Certificate Transfer Program Application Open
The New Jersey Economic Development Authority (EDA) is now accepting applications for the 2015 Technology Business Tax Certificate Transfer (NOL) Program. Please visit www.njeda.com/NOL for program information and access to the online application.
Congratulations to BioNJ Members Nominated as Healthcare Heroes!
BioNJ’s Chairman and CEO of PTC Therapeutics, Dr. Stuart Peltz, was nominated in the Innovation Hero category in NJBIZ’s Healthcare Heroes Competition. BioNJ Members Hackensack University Medical Center and Fairleigh Dickinson University were also nominated as finalists. Thank you to our Members for their continuous hard work and congratulations on being named finalists.
Click here for this week’s Weekender.